Summary
Substantial evidence now exists that oxidative stress may play an important role in the etiopathogenesis of DAT. The different sources of oxidative stress in DAT are suggesting several pharmacological opportunities for influencing the disease. It is possible to distinguish 2 major types of possible therapeutic agents according to their pharmacological point of attack.
-
1.
Radical scavengers, agents directly interacting with free radicals. Candidates of this type are gingko biloba, vitamins A, C, E and estrogen.
-
2.
Antioxidants, which are able to prevent or decrease the production of free radicals by use of specific neuropharmacological properties. Candidates are selegiline, a MAO-B inhibitor well established in the therapy of Parkinson’s disease, and tenilsetam, which is believed to be an AGE-inhibitor.
Recent in vitro studies have demonstrated the efficacy of both types of therapeutic agents by preventing or delaying oxidative neural damage.
Some clinical data exist regarding the antidementive properties particularly in terms of gingko biloba, selegiline and vitamin E. The efficacy studies about these compounds seem to indicate a promising future strategy in the therapy of DAT. But it is too early to draw definite conclusions since it is well kown that all of our candidate substances do not act specifically as radical scavengers or antioxidants.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Agnoli A, Martucci N, Fabbrini G, Buckley A, Fioravanti M (1990) Monoamine oxidase and dementia: treatment with an inhibitor of MAO-B activity. Dementia 1: 109–114
Agnoli A, Fabbrini G, Fioravanti M, Martucci N (1992) CBF and cognitive evaluation of Alzheimer type patients before and after MAO-B treatment: a pilot study. Eur Neuropharm 2: 31–35
Bell J, Beglan C, London E (1996) Interaction of ascorbic acid with the neurotoxic effects of NMDA and sodium nitroprusside. Life Sci 58: 367–371
Burke W, Ranno A, Roccaforte W, Wengel S, Bayer B, Willcockson N (1993a) L-deprenyl in the treatment of mild dementia of the Alzheimer type: preliminary results. J Am Geriatr Soc 41: 367–370
Burke W, Roccaforte W, Wengel S, Bayer B, Ranno A, Willcockson N (1993b) L-deprenyl in the treatment of mild dementia of the Alzheimer type: results of a 15-month trial. J Am Geriatr Soc 41: 1219–1225
Burns A, Marsh A, Bender D (1989) A trial of vitamin supplementation in senile dementia. Int J Ger Psychiat 4: 333–338
Burton G, Ingold K (1989) Vitamin E as an in vitro and vivo antioxidant. Ann NY Acad Sci 570: 7–21
Campi N, Todeschini GP, Scarzella L (1990) Selegiline versus 1-acetylcarnitine in the treatment of Alzheimer-type dementia. Clin Ther 12: 306–3314
Frei B, England L, Ames B (1989) Ascorbate is an outstanding antioxidant in human blood plasma. Proc Natl Acad Sci 86: 6377–6381
Frölich I, Riederer P (1995) Free radical mechanisms in dementia of Alzheimer type and the potential for antioxidative treatment. Drug Res 45: 443–446
Falsaperla A, Monici Preti PA, Oliani C (1990) Selegiline versus oxiracetam in patients with Alzheimer’s type dementia. Clin Ther 12: 376–384
Fahn S (1992) A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson’s disease. Ann Neurol 32: 128–132
Finali G, Piccirilli M, Oliani C, Piccinin GL (1991) L-deprenyl therapy improves verbal memory in amnestic Alzheimer patients. Clin Neuropharm 14: 523–536
Finali G, Piccirilli M, Oliani C, Piccinin GL (1992) Alzheimer-type dementia and verbal memory performance: influence of selegiline therapy. Ital J Neurol Sci 13: 141–148
Gardes-Albert M, Khalil A, Fortun A, Bonnefont-Rousselot D, Delattre J, Droy-Lefaix MT (1995) Protective effect of Gingko biloba extract (Egb 761) against the lipid peroxidation of low-density lipoproteins initiated by ·OH and O2· free radicals. In: Christen Y, Courtois Y, Droy-Lefaix MT (eds) Advances in gingko biloba research. Elsevier, Paris
Gerlach M, Riederer P, Youdim M (1995) Neuroprotective therapeutic strategies. Biochem Pharmacol 50: 1–16
Goad DL, Davis CM, Liem P, Fuselier CC, McCormack JR, Olsen KM (1991) The use of selegeline in Alzheimer’s patients with behavior problems. J Clin Psychiat 52:342–345
Gsell W, Conrad R, Hickethier M, Sofic E, Frölich L, Wichart I, Jellinger K, Moll G, Ransmayr G, Beckmann H, Riederer P (1965) Decreased catalase activity in brains of patients with dementia of Alzheimer type. J Neurochem 64: 1216–1223
Halliwell B (1992) Reactive oxygen species and the central nervous system. J Neurochem 59: 1609–1623
Hennekens C, Buring J, Peto R (1994) Antioxidant vitamins — benefits not yet proved. N Engl J Med 330: 1080–1081
Herrschaft H (1992) Zur klinischen Anwendung von Gingko biloba bei dementiellen Syndromen. Pharmazie in unserer Zeit 21: 266–275
Hofferberth B (1994) The efficacy of Egb 761 in patients with senile dementia of the Alzheimer type, a double blind, placebo-controlled study on different levels of investigation. Hum Psychopharmacol 9: 215–222
Hopfenmüller W (1994) Nachweis der therapeutischen Wirksamkeit eines Gingko biloba-Spezialextraktes. Drug Res 44: 1005–1013
Ihl R, Perisic I, Maurer K, Dierks T (1989) Effect of 3 months treatment with tenilsetam in patients suffering from dementia of Alzheimer type (DAT). J Neural Transm [PD-Sect] 1: 84–85
Jenner P (1994) Oxidative damage in neurodegenerative disease. Lancet 344: 796–798
Kanowski S, Herrmann WM, Staphan K, Wierich W, Hörr R (1996) Proof of efficacy of the Gingko biloba special extract Egb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer Type or multi-infarct dementia. Pharmacopsychiatry 29: 47–56
Kawas C, Resnick S, Morrison A, Brookmeyer R, Corrada M, Zonderman A, Bacal C, Donnell Lingle D, Metter E (1997) A prospective study of estrogen replacement therapy and the risk of developing Alzheimer’s disease: The Baltimore Longitudinal Study of Aging. Neurology 48: 1517–1521
Kleijnen J, Knipschild P (1992) Gingko biloba. Lancet 340: 1136–1139
Koutsilieri E, O’Callaghan JF, Chen TS, Riederer P, Rausch WD (1994) Selegiline enhances survival and neurite outgrowth of MPP+-treated dopaminergic neurons. Eur J Pharmacol 269: R3–R4
Lawlor B, Aisen P, Green C, Fine E, Schmeidler J (1997) Selegiline in the treatment of behavioural disturbance in Alzheimer’s disease. Int J Ger Psychiat 12: 319–322
Liebler D (1993) Antioxidant reactions of carotenoids. Ann NY Acad Sci 691: 20–31
Mangoni A, Grassi MP, Frattola L, Piolti R, Bassi S, Motta A, Marcone A, Smirne S (1991) Effects of a MAO-B inhibitor in the treatment of Alzheimer’s disease. Eur Neurol 31: 100–107
Martignoni E, Bono G, Blandini F, Sinforiani E, Merlo P, Nappi G (1991) Monoamines and related metabolite levels in the cerebrospinal fluid of patients with dementia of Alzheimer’s type. Influence of treatment with 1-deprenyl. J Neural Transm [PD-Sect] 3: 15–25
Meydani M (1995) Vitamin E. Lancet 345: 170–174
Monteverde A, Gnemmi P, Rossi F, Monteverde A (1990) Selegiline in the treatment of mild to moderate Alzheimer-type dementia. Clin Ther 12: 315–322
Münch G, Taneli Y, Schraven E, Schindler U, Schinzel R, Palm D, Riederer P (1994) The cognition-enhancing drug tenilsetam is an inhibitor of protein crosslinking by advanced glycosylation. J Neural Transm [PD-Sect] 8: 193–208
Münch G, Simm A, Double KL, Riederer P (1996) Commentary: oxidative stress and advanced glycation endproducts — parts of a vicious circle of neurodegeneration. Alzheimer’s Dis Rev 1: 71–74
Packer L, Haramaki N, Kawabata T, Marcocci L, Maitra I, Maguire JJ, Droy-Lefaix MT, Sebaki AH, Gardes-Albert M (1995) Gingko biloba extract (Egb 761): antioxidant action and prevention of oxidative stress-induced injury. In: Christen Y, Courtois Y, Droy-Lefaix MT (eds) Advances in Gingko biloba research, vol 4. Elsevier, Paris
Parkinson Study Group (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 328: 176–183
Parnetti L, Ambrosoli L, Abate G, Azzini C, Balestreri R, Bordin A, Crepaldi G, Christiani G, Cucinotta D (1995) Posatireline for the treatment of late onset Alzheimer’s disease: a double-blind multicentre study vs citicoline and ascorbic acid. Acta Neurol Scand 92: 135–140
Peyser CE, Folstein M, Chase GA, Starkstein S, Brandt J, Cockrell JR, Bylsma F, Coyle JT, McHugh PR, Folstein SE (1995) Trial of d-α-Tocopherol in Huntington’s disease. Am J Psychiatry 152: 1771–1775
Piccinin GL, Final G, Piccirilli M (1990) Neuropsychological effects of 1-deprenyl in Alzheimer’s type dementia. Clin Neuropharm 13: 147–163
Sano M, Ernesto C, Thomas R, Klauber M, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman C, Pfreifer E, Schneider L, Thal L (1997) A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. N Engl J Med 336: 1216–1222
Schneider L, Pollo V, Zemansky M, Gleason R, Palmer R, Sloane B (1991) A pilot study of low-dose 1-deprenyl in Alzheimer’s disease. J Ger Psychiat Neurol 4: 143–148
Schneider L, Olin J, Pawluczyk S (1993) A double-blind crossover pilot study of 1-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer’s disease. Am J Psychiatry 150: 321–323
Smith MA, Sayre L, Perry G (1996) Is Alzheimer’s a disease of oxidative stress? Alzheimer’s Dis Rev 1: 63–67
Sunderland T, Tariot PN, Cohen RM, Newhouse PA, Mellow AM, Mueller EA, Murphy DL (1987) Dose-dependent effects of deprenyl on CSF metabolites in patients with Alzheimer’s disease. Psychopharmacology 91: 293–296
Tariot P, Cohen R, Sunderland T, Newhouse P, Yount D, Mellow A, Weingartner H, Mueller E, Murphy D (1987) L-deprenyl in Alzheimer’s disease. Arch Gen Psychiatry 44: 427–433
Tariot P, Sunderland T, Weingartner H, Murphy D, Welkowitz J, Thompson K, Cohen R (1987) Cognitive effects of 1-deprenyl in Alzheimer’s disease. Psychopharmacology 91: 489–495
Thome J, Gsell W, Rösier M, Kornhuber J, Frölich I, Hashimoto E, Zielke B, Wiesbeck G, Riederer P (1996) Oxidative stress associated parameters (lactoferrin, superoxide dismutase) in serum of patients with Alzheimer’s disease. Life Sci 60: 13–19
Weitbrecht WU, Jansen W (1986) Primär degenerative Demenz: Therapie mit Gingkobiloba-Extrakt. Fortschr Med 104: 199–202
White HL, Scates P, Cooper BR (1996) Extracts of Gingko biloba leaves inhibit monoamine oxidase. Life Sci 58: 1315–1321
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer-Verlag/Wien
About this paper
Cite this paper
Rösler, M., Retz, W., Thome, J., Riederer, P. (1998). Free radicals in Alzheimer’s dementia: currently available therapeutic strategies. In: Gertz, HJ., Arendt, T. (eds) Alzheimer’s Disease — From Basic Research to Clinical Applications. Journal of Neural Transmission. Supplementa, vol 54. Springer, Vienna. https://doi.org/10.1007/978-3-7091-7508-8_21
Download citation
DOI: https://doi.org/10.1007/978-3-7091-7508-8_21
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-83112-0
Online ISBN: 978-3-7091-7508-8
eBook Packages: Springer Book Archive